EUVIMEDEUVIMED entdecken
Open Access

NOSH-aspirin (NBS-1120) inhibits estrogen receptor–negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways

Mitali Chattopadhyay, Niharika Nath, Ravinder Kodela, Shalaka Metkar, Sarin A Soyemi, Khosrow Kashfi

The Journal of Pharmacology and Experimental Therapeutics · 2025

DOI: 10.1124/jpet.124.002240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2025. Verfasst von Mitali Chattopadhyay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medici…. Hauptthemen laut MEDLINE: Aspirin, Signal Transduction, Receptors, Estrogen, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, NIH, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinSignal TransductionReceptors, EstrogenBreast NeoplasmsAntineoplastic AgentsHumansAnimalsFemaleMiceCell Line, TumorOxidation-ReductionApoptosisXenograft Model Antitumor AssaysCell ProliferationForkhead Box Protein M1Reactive Oxygen SpeciesMice, NudeNitric Oxide

Stichwörter der Autor:innen

Breast cancerEstrogen receptor-negative breast cancerForkhead box M1, nitric oxide, and hydrogen sulfideNitric oxide-hydrogen sulfide–releasing aspirinReactive oxygen species

Substanzen

AspirinReceptors, EstrogenForkhead Box Protein M1Reactive Oxygen SpeciesAntineoplastic AgentsNitric Oxide

Autor:innen und Institutionen

  • Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, New York.
  • Department of Biological and Chemical Sciences, New York Institute of Technology, New York, New York.
  • Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, New York; Graduate Program in Biology, City University o…

Förderung

  • NIMHD NIH HHS
  • NIH
  • National Cancer Institute

Zitieren

APA

Chattopadhyay, M., Nath, N., Kodela, R., Metkar, S., Soyemi, S. A., & Kashfi, K. (2025). NOSH-aspirin (NBS-1120) inhibits estrogen receptor–negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.124.002240

Vancouver

Chattopadhyay M, Nath N, Kodela R, Metkar S, Soyemi SA, Kashfi K. NOSH-aspirin (NBS-1120) inhibits estrogen receptor–negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways. The Journal of Pharmacology and Experimental Therapeutics. 2025. doi:10.1124/jpet.124.002240

BibTeX
@article{Chattopadhyay2025,
  author = {Chattopadhyay, Mitali and Nath, Niharika and Kodela, Ravinder and Metkar, Shalaka and Soyemi, Sarin A and Kashfi, Khosrow},
  title = {NOSH-aspirin (NBS-1120) inhibits estrogen receptor–negative breast cancer in vitro and in vivo by modulating redox-sensitive signaling pathways},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2025},
  doi = {10.1124/jpet.124.002240}
}
Kostenlos starten →